Optimizing the Cas13 antiviral train: cargo and delivery.
Optimizing the Cas13 antiviral train: cargo and delivery.
复制标题
DOI：
10.15252/emmm.202217146
复制
发表时间：
2023-07-10
影响因子：
11.1
通讯作者：
中科院分区：
文献类型：
--
作者：
2020年的严重急性呼吸系统综合症冠状病毒2型（SARS‐CoV‐2）大流行凸显了对传染病采取快速、广泛应对措施的必要性。其中一项创新使用CRISPR-Cas 13技术直接靶向和切割病毒RNA，从而抑制复制。由于其可编程性，基于Cas 13的抗病毒疗法可以快速部署，以针对新出现的病毒，而传统的治疗开发至少需要12-18个月，通常需要多年。此外，与mRNA疫苗的可编程性类似，Cas 13抗病毒药物可以随着病毒的进化而开发，以靶向突变。本评论讨论了基于Cas 13的抗病毒疗法的发展和潜在的临床转化。
The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic in 2020 highlighted the need for rapid, widespread responses against infectious disease. One such innovation uses CRISPR‐Cas13 technology to directly target and cleave viral RNA, thereby inhibiting replication. Due to their programmability, Cas13‐based antiviral therapies can be rapidly deployed to target emerging viruses, in comparison with traditional therapeutic development that takes at least 12–18 months, and often many years. Moreover, similar to the programmability of mRNA vaccines, Cas13 antivirals can be developed to target mutations as the virus evolves. This Commentary discusses the development and potential clinical translation of the Cas13‐based antiviral therapies.